Trials / Completed
CompletedNCT00542035
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP ANALGESIC EFFICACY TRIAL OF ORAL ARRY-371797 IN SUBJECTS UNDERGOING THIRD MOLAR EXTRACTION
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain either perioperatively or postoperatively in a third molar extraction pain model, and to further evaluate the drug's safety. Approximately 150 subjects from the US will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-371797, p38 inhibitor; oral | dose 1, dose 2 |
| DRUG | Placebo; oral | dose 1, dose 2 |
| DRUG | Placebo; oral | dose 1 |
| DRUG | ARRY-371797, p38 inhibitor; oral | dose 2 |
Timeline
- Start date
- 2007-11-11
- Primary completion
- 2008-02-11
- Completion
- 2008-02-11
- First posted
- 2007-10-10
- Last updated
- 2021-02-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00542035. Inclusion in this directory is not an endorsement.